Successful Treatment of Refractory Dermatomyositis with Deucravacitinib (Sotyktu): A Case Report.

ABSTRACT:

Introduction

Clinically amyopathic dermatomyositis (CADM) is a subtype of dermatomyositis (DM) characterized by cutaneous findings without clinically apparent muscle involvement. While immunosuppressive therapies such as methotrexate, mycophenolate mofetil, and hydroxychloroquine are commonly used, treatment-resistant cases remain a challenge. We present a case of refractory CADM successfully treated with deucravacitinib, a selective TYK2 inhibitor.

Case presentation

A 50-year-old woman with a 3-year history of CADM presented with persistent facial erythema, heliotrope rash, violaceous erythema on sun-exposed areas, and Gottron's sign. Despite multiple systemic treatments, including methotrexate, mycophenolate mofetil, hydroxychloroquine, and topical and oral roflumilast, sh

SUBMITTER: Lapa T 

PROVIDER: S-EPMC12503779 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature